It targets vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor, hepatocyte factor receptor, fibroblast growth factor receptor, and other signaling targets, facilitating apoptosis, mitigating angiogenesis, and suppressing tumor cell proliferation. This evidence concerns the gene KDR and neoplasm.